Logo of the International Congress on Porphyrins and Porphyrias 2015

International Congress on Porphyrins and Porphyrias

Sept 14th – Sept 16th 2015, Düsseldorf, Germany

Scientific Program for Monday September 14th, 2015

08:00 - 17:30
Registration and poster set up

Theme: The non-acute porphyrias

08:45 - 09:00
Welcome address
Jorge Frank (congress president)
Jean-Charles Deybach (president EPNET)

Session 1

Chair: Jorge Frank (Germany) and Jean-Charles Deybach (France)

09:00 - 09:45
Plenary lecture 1: »New risk factors contributing to porphyria cutanea tarda.«
John Phillips, USA
09:45 - 10:45
Selected oral presentations
1. Relapse of porphyria cutanea tarda after achieving remission: A meta-analysis
Ashwani Singal et al., USA
2. Porphyria cutanea tarda following multi-agent chemotherapy in children: A report of two cases.
Akshata Moghe et al., USA
3. Direct-acting antiviral agents in patients with porphyria cutanea tarda co-infected with hepatitis C virus and human immunodeficiency virus.
Paula Aguilera et al., Spain
4. Identification of polymorphic GNPAT as a risk factor for porphyria cutanea tarda.
Colin Farrell et al., USA
10:45 - 11:15
Coffee break

Session 2

Chair: Karl Anderson (USA) and Michael Badminton (Wales)

11:15 - 12:00
Plenary lecture 2: »The implications of marketing authorization for Scenesse®.«
Janneke Langendonk, Netherlands
12:00 - 12:30
Selected oral presentations
5. Update on long-term observation of afamelanotide (Scenesse®)-treatment in 146 Swiss and Italian patients with erythropoietic protoporphyria.
Elisabeth Minder et al., Switzerland
6. Variation in erythrocyte and plasma protoporphyrin levels over time in protoporphyrias.
Eric Gou et al., USA
12:30 - 12:45
Introduction to the EPNET Asscociation
Aasne Aarsand
Sverre Sandberg
Jean-Charles Deybach
12:45 - 14:45
EPNET General Assembly
Jean-Charles Deybach
EPNET members (with sandwiches)
12:45 - 14:45
Lunch break and poster viewing

Session 3

Chair: Joanne T. Marsden (England) and J.H. Paul Wilson (Netherlands)

14:45 - 15:30
Plenary lecture 3: »Prospects for a splice modulating therapy for EPP.«
Laurent Gouya, France
15:30 - 16:00
Selected oral presentations
7. Introducing Porphyria Light Factor (PLF): A special prediction of light intensity for EPP patients.
Atle Brun et al., Norway
8. Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP): Clinical, biochemical and molecular characterization of North American patients.
Manisha Balwani et al., USA
16:00 - 16:15
Coffee break

Session 4

Chair: Sverre Sandberg (Norway) and John Phillips (USA)

16:15 - 17:15
Selected oral presentations
9. Photo hen’s egg test: Protective effects of β-carotene and melanin against protoporphyrin IX-induced phototoxicity.
Pascal Robert Bafteh et al., Switzerland
10. Intravenous iron therapy in XLDPP? A single family experience.
Mark Sonderup et al., South Africa
11. Assessment of anxiety, depression, and illness perception in patients with erythropoietic protoporphyria (EPP).
Hetanshi Naik et al., USA
12. Osteoporosis in patients with erythropoietic protoporphyria.
Maaike Biewenga et al., Netherlands
17:15 - 18:45
Reception for all conference attendees with drinks / light appetizers